Mepolizumab for chronic rhinosinusitis with nasal polyps
- PMID: 33872589
- DOI: 10.1016/S2213-2600(21)00133-8
Mepolizumab for chronic rhinosinusitis with nasal polyps
Conflict of interest statement
GGB has received honoraria for lectures or advisory boards, or both, from Amgen, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi-Genzyme, and Teva. PG has received consulting fees, honoraria for lectures or research funding, or both, from 3NT Medical, ALK, Argenx, AstraZeneca, Genentech, Hall Allergy, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi-Genzyme, Stallergenes Greer, and Teva.
Comment in
-
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872587
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
